Fiquem ligados nas últimas notícias em DII! Use a hashtag #novidadesdii e fique sabendo das novidades no tratamento das DII (Doenças Inflamatórias Intestinais).
Em breve novo tratamento para #fistulas:
“The ADMIRE-CD trial is a randomized, double-blind, placebo-controlled, Phase 3 study, designed to investigate the efficacy and safety of a single treatment of Cx601 for the treatment of complex perianal fistulas in Crohn’s disease patients. A significantly greater proportion of patients in the Cx601 group versus the placebo group achieved the primary endpoint of combined #remission (defined as clinical assessment of closure of all treated external openings draining at baseline, despite gentle finger compression, and absence of collections >2cm confirmed by MRI) at week 24 in the ITT population 53 (50%) of 107 vs 36 of 105 (34%), respectively (97.5% CI 0.2–30.3; p=0.024) and the mITT population 53 (51%) of 103 vs 36 (36%) of 101 (0.5–31.2; p=0.021). These results were confirmed in the per-protocol population and in additional supportive and sensitivity analyses. This definition of remission is more stringent than those commonly used in clinical trials on #perianal #fistulizing disease, as it includes both clinical and radiological assessment by MRI.2,3 Treatment-emergent adverse (non-serious and serious) and discontinuations due to adverse events were comparable between Cx601 and placebo arms.”
(…)
“About Cx601:
Cx601 is a suspension of allogeneic expanded adipose-derived #stemcells(eASC) locally injected. Cx601 is an investigational agent being developed for the treatment of complex perianal fistulas in Crohn’s disease patients that failed conventional therapy including antibiotics, immunosuppressant, or anti-TNF therapy. Crohn’s disease is a chronic inflammatory disease of the #intestine and patients can suffer from complex perianal fistulas for which there is currently no effective treatment.”
Cx601 is a suspension of allogeneic expanded adipose-derived #stemcells(eASC) locally injected. Cx601 is an investigational agent being developed for the treatment of complex perianal fistulas in Crohn’s disease patients that failed conventional therapy including antibiotics, immunosuppressant, or anti-TNF therapy. Crohn’s disease is a chronic inflammatory disease of the #intestine and patients can suffer from complex perianal fistulas for which there is currently no effective treatment.”
Leia toda a notícia aqui:http://www.takeda.com/news/2016/20160802_7503.html
OBS.: Coloquei o tradutor do Google aqui no blog, você pode usar! Você encontra do lado direito do blog. Não é uma tradução fiel, mas dá para entender a mensagem. São muitas novidades acontecendo pelo mundo sobre as doenças inflamatórias intestinais e se eu for traduzir todas vou levar um certo tempo, então achei melhor compartilhar com vocês a íntegra para que todos tenham acesso as informações. Também indico outro tradutor o http://www.bing.com/translator, mas aí você terá que copiar o texto e colar lá no Bing.
